Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Proteostasis signs on Biogen Idec to help with Usp14 inhibitor program

Executive Summary

Proteostasis Therapeutics Inc. (developing therapies for orphan and regenerative diseases and cystic fibrosis) and Biogen Idec Inc. have signed a worldwide R&D deal involving therapeutics that inhibit the ubiquitin specific peptidase 14 (Usp14) enzyme, offering a disease-modifying approach to conditions involving toxic protein aggregation.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies